PHAXIAM Therapeutics
Iman El-Hariry is currently serving as the Chief Medical Officer at ERYTECH Pharma since January 2015. Prior to this role, she held the position of President at Azure Oncology Consulting from July 2014 to July 2015. With extensive experience in the pharmaceutical industry, Iman has also worked at Synta Pharmaceuticals as the VP of Clinical Research and at Astellas Pharma as the Global Head of Oncology. She has a strong background in clinical development, strategic planning, and overseeing clinical trials, particularly in the field of oncology. Iman's educational background includes a PhD in Cancer Research from Imperial College London and an MD in Oncology from Alexandria University.
This person is not in the org chart
This person is not in any offices
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.